Embecta logged a -4.2% change during today's afternoon session, and is now trading at a price of $24.86 per share. The S&P 500 index moved -0.7%. EMBC's trading volume is 415,218 compared to the stock's average volume of 622,519.
Embecta trades -11.21% away from its average analyst target price of $28 per share. The 2 analysts following the stock have set target prices ranging from $25 to $31, and on average have given Embecta a rating of hold.
If you are considering an investment in EMBC, you'll want to know the following:
-
Embecta has moved -44.8% over the last year, and the S&P 500 logged a change of -19.2%
-
Based on its trailing earning per share of 3.89, Embecta has a trailing 12 month Price to Earnings (P/E) ratio of 6.4 while the S&P 500 average is 15.97
-
EMBC has a forward P/E ratio of 11.0 based on its forward 12 month price to earnings (Eps) of $2.26 per share
-
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes.
-
Based in Parsippany, the company has 1,900 full time employees and a market cap of $1,418,862,208. Embecta currently returns an annual dividend yield of 0.6%.
